Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe

BACKGROUND: Approximately 164,000 deaths yearly are due to shigellosis, primarily in developing countries. Thus, a safe and affordable Shigella vaccine is an important public health priority. The GSK Vaccines Institute for Global Health (GVGH) developed a candidate Shigella sonnei vaccine (1790GAHB)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EBioMedicine
Main Authors: Launay, Odile, Lewis, David J.M., Anemona, Alessandra, Loulergue, Pierre, Leahy, Jo, Sciré, Antonella Silvia, Maugard, Anaïs, Marchetti, Elisa, Zancan, Stefano, Huo, Zhiming, Rondini, Simona, Marhaba, Rachid, Finco, Oretta, Martin, Laura B., Auerbach, Jochen, Cohen, Daniel, Saul, Allan, Gerke, Christiane, Podda, Audino
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5552227/
https://ncbi.nlm.nih.gov/pubmed/28735965
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2017.07.013
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados